Soluble Fas in serum from patients with renal cell carcinoma

Nonomura, Norio; Nishimura, Kazuo; Ono, Yutaka; Fukui, Toshikazu; Harada, Yasunori; Takaha, Natsuki; Takahara, Shiro; Okuyama, Äkïhïko

doi:10.1016/s0090-4295(99)00379-9

Cited by 30 publications

(34 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3-6 months) may be required to see if sFas levels decrease. Cultured renal cell cancer cells did not produce sFas into the culture supernatant [10]. It has been reported that sFas is produced elsewhere in response to a tumor and that elevation of sFas reflects the tumor burden in renal cell cancer [10].…”

Section: Discussionmentioning

confidence: 95%

“…Cultured renal cell cancer cells did not produce sFas into the culture supernatant [10]. It has been reported that sFas is produced elsewhere in response to a tumor and that elevation of sFas reflects the tumor burden in renal cell cancer [10]. sFas might be produced by activated lymphocytes and stromal tissues surrounding the tumor in response to immune activation.…”

Section: Discussionmentioning

confidence: 98%

“…The chimeric sFas fusion molecule, which is composed of the extracellular domain of Fas and the Fc portion of human IgG, abrogates Fas-dependent CTL activity [20]. Recently an elevated soluble form of Fas has been identified in the serum of patients with cervical, ovarian, bladder, renal cell, colon, breast and hepatocellular cancer [7][8][9][10][11][12]. The sFas levels in patients with prostate cancer have been reported to be significantly higher than those without cancer [13].…”

Section: Discussionmentioning

confidence: 99%

“…Judo et al reported that surgical removal of a hepatocellular carcinoma reduced sFas levels to negative values within the first postoperative week [12]. Nonomura et al also reported that sFas levels in patients with renal cell cancer were correlated with tumor size and significantly decreased following nephrectomy [10]. Prostate cancer specimens have been reported to express Fas antigen by immunohistochemical analysis [21].…”

Section: Discussionmentioning

confidence: 99%

“…sFas binds to and neutralizes Fas ligand, thereby functionally antagonizing the Fas-Fas ligand pathway [6]. Recently serum sFas has been reported to be elevated in patients with malignant diseases including prostate cancer [7][8][9][10][11][12][13]. Patients diagnosed with prostate cancer have also been shown to have significantly higher levels of serum sFas than those with benign prostate hyperplasia [13].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Prognostic Significance of Serum Soluble Fas Level and Its Change during Regression and Progression of Advanced Prostate Cancer

2003

View full text Add to dashboard Cite

Abstract. To evaluate the clinical usefulness of serum soluble Fas (sFas) and sFas ligand as a prognostic factor and for monitoring the regression and progression of metastatic prostate cancer treated with endocrine therapy, sFas and sFas ligand were measured in sera collected from 30 patients with untreated metastatic prostate cancer. sFas levels were measured sequentially in 16 patients who had progressed to a state of elevated prostate-specific antigen (PSA) and 5 patients who were in regression following endocrine therapy. Serum sFas levels in patients with metastatic prostate cancer were found to be significantly higher than that of control patients with benign prostate hyperplasia. Patients with low levels of serum sFas had a higher cause-specific survival rate and a higher PSA progression-free rate compared with patients with high levels of serum sFas. In patients who suffered PSA progression following endocrine therapy, serum sFas increased in parallel to the increase in PSA levels although the magnitude of change in sFas was very small. In patients whose tumor regressed following therapy, sFas levels did not change. sFas ligand levels were very low or below measurable levels in all specimens. sFas levels might be associated with poor prognosis in metastatic prostate cancer. Serum sFas ligand appears to have limited clinical relevance.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Significance of Serum Soluble Fas Level and Its Change during Regression and Progression of Advanced Prostate Cancer

2003

View full text Add to dashboard Cite

show abstract

sFas levels increase in response to cisplatin‐based chemotherapy in lung cancer patients

Ulukaya

Acılan

Yilmaz

et al. 2010

Cell Biochemistry & Function

View full text Add to dashboard Cite

The Fas/Fas Ligand (FasL) system and survivin have counteracting roles in cell survival. Therefore, we explored the role of circulating soluble Fas (sFas) and the tissue levels of Fas and survivin with regard to response to chemotherapy in lung cancer patients. Serum samples from 52 lung cancer patients and 54 control subjects (19 benign lung disease and 35 healthy control subjects) were collected prior to and 24 and 48 h after chemotherapy. sFas was statistically significantly higher in the cancer group than that in the control groups (p < 0.001). Baseline (before chemotherapy) sFas values showed a statistically significant inverse correlation with overall survival (r = -0.599, p < 0.001). There was a significant increase in serum sFas levels 24 h after treatment (p < 0.05). Contrarily, tissue levels of Fas and survivin were not changed following the chemotherapy (p > 0,05). In conclusion, increased sFas may be an indicator of poor outcome in lung cancer patients. However, cisplatin-based chemotherapy may not be effective via neither the Fas/FasL system nor survivin pathway. Indeed, larger sample size is required for further evaluation.

show abstract

Serum soluble Fas levels and prediction of response to platinum‐based chemotherapy in epithelial ovarian cancer

Chaudhry

Srinivasan

Patel

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is treated mainly by platinumbased combination chemotherapy. Chemotherapy induces apoptosis in which the Fas/Fas ligand pathway is important. Serum soluble Fas (sFas) is a biomarker of this pathway and functionally inhibits Fas-/FasL-mediated apoptosis. In this study, we have investigated the role of sFas in prediction of response to chemotherapy in EOC. Thirty-five patients were recruited and their serum sFas levels were estimated by ELISA at 4 time points-preoperative (sFas1), postoperative (sFas2), midchemotherapy (sFas3) and at the end of chemotherapy (sFas4). The response to chemotherapy was documented clinically, radiologically and by CA-125 levels, based on which, 2 groups were identified: primary chemosensitive (n 5 24) and primary chemoresistant (n 5 11). Based on the disease status at last follow-up, 2 groups were identified: No Evidence of Disease (n 5 15) and Evidence of Disease (n 5 20). The primary chemoresistant tumors showed significantly higher median sFas2 levels (p 5 0.033) with the sFas2/sFas1 ratio ‡1 (p 5 0.001). A multivariate Cox proportional hazards regression model identified sFas2/sFas1 ratio as a significant factor for the prediction of response to platinum-based chemotherapy (p 5 0.011). Receiver operating characteristic (ROC) analysis showed that at a ratio of 1.2, sFas2/sFas1 achieved a sensitivity of 82% and specificity of 100% for prediction of chemotherapeutic response. sFas2/ sFas1 and sFas3/sFas1 ratio was also higher in patients with evidence of disease (p 5 0.018 and p 5 0.028, respectively). Progression-free survival rates in patients with sFas2/sFas1 ratio <1 exceeded those with ratio ‡1 (p 5 0.004). In conclusion, serum sFas is a useful biomarker for predicting response to platinumbased chemotherapy in EOC. ' 2007 Wiley-Liss, Inc.

show abstract

Soluble Fas in serum from patients with renal cell carcinoma

Cited by 30 publications

References 15 publications

Prognostic Significance of Serum Soluble Fas Level and Its Change during Regression and Progression of Advanced Prostate Cancer

Prognostic Significance of Serum Soluble Fas Level and Its Change during Regression and Progression of Advanced Prostate Cancer

sFas levels increase in response to cisplatin‐based chemotherapy in lung cancer patients

Serum soluble Fas levels and prediction of response to platinum‐based chemotherapy in epithelial ovarian cancer

Contact Info

Product

Resources

About